Latest on Ultrasound Renal Denervation

Published: 22 June 2022

  • Views:

    Views Icon 7682
  • Likes:

    Heart Icon 7
  • episode_image
    1h 4m 58s
    Part 7 | Session 1 ACC 2022 Symposium
    Michael Weber, Felix Mahfoud, Ajay J Kirtane, Michael Bloch
  • episode_image
    59m 32s
    Part 7 | Session 2 TCT 2021 Symposium
    Chandan Devireddy, Ajay J Kirtane, Felix Mahfoud, Naomi Fisher
Average (ratings)
No ratings
Your rating


Ultrasound Renal Denervation (uRDN) is an innovative therapy option for the treatment of uncontrolled hypertension. uRDN therapy is delivered in a minimally invasive procedure that may lower high blood pressure by treating overactive renal nerves with ultrasound energy.


This page provides an overview of uRDN technology and the latest evidence from its associated RADIANCE clinical program.


The PARADISETM System is Limited to Investigational Use Only in the United States. Approved for distribution in CE mark countries only.
This educational content is supported by:

What you will learn:

  • How uRDN works and its potential benefits for patients suffering from uncontrolled hypertension
  • The clinical evidence supporting uRDN and its implications for the field of hypertension
  • The process for building a uRDN centre and therapy network

This page is designed for:

  • Interventional cardiologists
  • General cardiologists
  • Hypertension specialists
  • Nephrologists
  • Interventional radiologists

More from this programme

Part 4

RADIANCE II Pivotal Trial for Paradise Ultrasound Renal Denervation System in Patients With Hypertension

Part 6

Patient Perspective & Provider Referral Development

Understand patient preference and referral development

Part 7

Discussion With Experts

Faculty Biographies

Joost Daemen

Joost Daemen

Interventional Cardiologist

Dr Joost Daemen is a senior interventional cardiologist at the Thorax Center, Erasmus MC, Rotterdam, NL. Dr Daemen obtained his degree in medicine at the Erasmus University Medical Center. He is actively involved in several drug-eluting stent trials and is Principal Investigator of four trials focusing on the safety and efficacy of renal sympathetic denervation in hypertension, heart failure, vasospastic angina and heart failure. Dr Daemen is a member of the editorial board of EuroIntervention and the Netherlands Heart Journal, member of Young ICIN, and has completed courses in biomedical statistics and device training.

View full profile
Atul Pathak

Atul Pathak


Dr Atul Pathak is a Pharmacologist and Cardiologist. He is leading a clinical research team focusing on cardiovascular pathophysiology and clinical pharmacology and is affiliated to INSERM (National Institute of Medical Research).

Dr Pathak has been awarded by the ESC (Young Investigator Award), by the British Pharmacological Society and the French Society of Cardiology. He is also member of the French Association of Pharmacologists, the French Society of Hypertension and Cardiology, the American Society for Heart Failure. He is elected President of the Cardiovascular Pharmacology Working Group of the French Society of Cardiology. He has both academic and institutional commitments, among them participation at advisory board at AFSSAPS (French FDA) and HAS for the review of clinical trials protocol, assessment of benefit /risk ratio of drugs (marketed or under development) and medico-economic issues (regarding lipid or blood pressure lowering drugs).

View full profile
Joachim Weil

Joachim Weil

Prof Joachim Weil is the Head of the Medical Department II - Cardiology and Angiology of the Sana Hospitals Lübeck. As a modern competence center, the Department of Cardiology and Angiology offers highly specialized medical services in addition to cardiological care. In addition, Sana Hospitals Lübeck cooperates closely with the University Hospital of Schleswig-Holstein.

Professor Joachim Weil is one of Germany's renowned experts in the treatment of cardiovascular diseases and has received the Focus Award "TOP Physician - Hypertension" several times. He has longstanding experience especially in the field of renal denervation and is head of the clinical research group.

View full profile